

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2)	<p>Studies in mice suggest that inhibiting the oxygen sensor PHD2 could be useful for improving the delivery of chemotherapeutics. In Phd2-deficient mice, implanted tumors showed better perfusion and oxygenation and less tumor cell invasion, intravasation and metastasis than tumors in wild-type mice. Next steps include investigating both the oncogenic and tumor-suppressor effects of PHD2 inhibition in cancer cells and tumor models.</p> <p><b>SciBX 2(8); doi:10.1038/scibx.2009.309</b>  <b>Published online Feb. 26, 2009</b></p>	Patent and licensing status unavailable	<p>Mazzone, M. <i>et al. Cell</i>; published online Feb. 15, 2009;            doi:10.1016/j.cell.2009.01.020</p> <p><b>Contact:</b> Peter Carmeliet, Catholic University Leuven, Leuven, Belgium            e-mail:  <a href="mailto:peter.carmeliet@med.kuleuven.be">peter.carmeliet@med.kuleuven.be</a></p>